{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T21:39:53Z","timestamp":1649021993548},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Revista Internacional de Androlog\u00eda"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.androl.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T21:50:58Z","timestamp":1594936258000},"source":"Crossref","is-referenced-by-count":0,"title":["Recomenda\u00e7\u00f5es em HPV Masculino da Sociedade Portuguesa de Andrologia, Medicina Sexual e Reprodu\u00e7\u00e3o: Preven\u00e7\u00e3o"],"prefix":"10.1016","author":[{"given":"Pedro","family":"Eufr\u00e1sio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Jorge Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Gra\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Palmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicidade","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edlvio","family":"Bollini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Rebelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pepe","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Tomada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Vendeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.androl.2020.01.005_bib0250","series-title":"Sexually Transmitted Diseases","author":"Marr","year":"2007"},{"key":"10.1016\/j.androl.2020.01.005_bib0255","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/infdis\/jit191","article-title":"Consistent condom use reduces the genital human papillomavirus burden among high-risk men: the HPV infection in men study","volume":"208","author":"Pierce Campbell","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.androl.2020.01.005_bib0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00007435-199703000-00007","article-title":"An in vitro evaluation of condoms as barriers to a small virus","volume":"24","author":"Lytle","year":"1997","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.androl.2020.01.005_bib0265","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1086\/597619","article-title":"Anogenital hairs are an important reservoir of alpha-papillomaviruses in patients with genital warts","volume":"199","author":"Poljak","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.androl.2020.01.005_bib0270","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1071\/SH11095","article-title":"Condom use errors and problems: a global view","volume":"9","author":"Sanders","year":"2012","journal-title":"Sex Health"},{"key":"10.1016\/j.androl.2020.01.005_bib0275","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/03630242.2014.979970","article-title":"HPV knowledge and factors associated with intention to use condoms for reducing HPV infection risk among adolescent women in Taiwan","volume":"55","author":"Tu","year":"2015","journal-title":"Women Health"},{"key":"10.1016\/j.androl.2020.01.005_bib0280","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0969141314522454","article-title":"Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies","volume":"21","author":"Lam","year":"2014","journal-title":"J Med Screen"},{"key":"10.1016\/j.androl.2020.01.005_bib0285","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa0802556","article-title":"Male circumcision for the prevention of HSV-2 and HPV infections and syphilis","volume":"360","author":"Tobian","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.androl.2020.01.005_bib0290","first-page":"657","article-title":"Male circumcision for HIV prevention in men in Rakai","volume":"369","author":"Gray","year":"2007","journal-title":"Uganda: a randomised trial. Lancet"},{"key":"10.1016\/j.androl.2020.01.005_bib0295","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1371\/journal.pmed.0020298","article-title":"Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial","volume":"2","author":"Auvert","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.androl.2020.01.005_bib0300","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/bmj.320.7249.1592","article-title":"How does male circumcision protect against HIV infection?","volume":"320","author":"Szabo","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.androl.2020.01.005_bib0305","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to cl\u00ednical application","volume":"2","author":"Zur Hausen","year":"2002","journal-title":"Nat Res Cancer."},{"key":"10.1016\/j.androl.2020.01.005_bib0310","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer."},{"key":"10.1016\/j.androl.2020.01.005_bib0315","first-page":"477","article-title":"Currently Approved Prophylactic HPV Vaccines","volume":"10","author":"Harper","year":"2010","journal-title":"Expert Opin Biol Ther."},{"key":"10.1016\/j.androl.2020.01.005_bib0320","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.androl.2020.01.005_bib0325","first-page":"1","article-title":"A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines","volume":"30","author":"Schiller","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.androl.2020.01.005_bib0330","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eimc.2015.03.018","article-title":"Vacuna frente al virus del papiloma humano Eficacia y seguridad","volume":"33","author":"Bruni","year":"2015","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.androl.2020.01.005_bib0335","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1086\/522864","article-title":"Prophylactic efficacy of a quadrivalent HPV (type 6,11,16,18) vaccine in Women with virologic evidence of HPV infection","volume":"196","author":"Ferris","year":"2007","journal-title":"J Infect Disease"},{"key":"10.1016\/j.androl.2020.01.005_bib0340","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Human Vaccines."},{"key":"10.1016\/j.androl.2020.01.005_bib0345","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/jdv.14311","article-title":"Epidemiology of human papillomavirus on anogenital warts in Portugal - The HERCOLES study","volume":"31","author":"Azevedo","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.androl.2020.01.005_bib0350","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid dcline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.androl.2020.01.005_bib0355","first-page":"13","article-title":"Inclusion of the benefits of enhance cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","author":"Westra","year":"2013","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.androl.2020.01.005_bib0360","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males","volume":"364","author":"Giuliano","year":"2011","journal-title":"NEJM."},{"key":"10.1016\/j.androl.2020.01.005_bib0365","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/OLQ.0000000000000418","article-title":"Significant Reduction in Incidence of Genital Warts in Young Men 5 years Into the Danish Human Papillomavirus Vaccination Program for Girls and Women","volume":"43","author":"Bollerup","year":"2016","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.androl.2020.01.005_bib0370","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirs vaccination programes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.androl.2020.01.005_bib0375","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.vaccine.2015.12.063","article-title":"Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine."},{"key":"10.1016\/j.androl.2020.01.005_bib0380","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.androl.2020.01.005_bib0385","unstructured":"Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV. National Center for Immunization and Respiratory Diseases. 2016."},{"key":"10.1016\/j.androl.2020.01.005_bib0390","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000000773","article-title":"A randomized, double-blind, phase iii study of the immunogenicity and safety of a 9-valent human papillomavirus l1 virus-like particle vaccine (V503) versus Gardasil\u00ae in 9-15-year-old girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.androl.2020.01.005_bib0395","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/INF.0000000000000694","article-title":"An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age","volume":"34","author":"Kosalaraksa","year":"2015","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.androl.2020.01.005_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics."},{"key":"10.1016\/j.androl.2020.01.005_bib0405","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1016\/j.vaccine.2015.06.088","article-title":"Immunogenicity and safety of the 9-valent HPV vaccine in men","volume":"33","author":"Castellsagu\u00e9","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.androl.2020.01.005_bib0410","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine."},{"key":"10.1016\/j.androl.2020.01.005_bib0415","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1055-9965.EPI-13-0053","article-title":"Age-specific occurrence of HPV16- and HPV18-related cervical cancer","volume":"22","author":"De Sanjose","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.androl.2020.01.005_bib0420","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1055-9965.EPI-13-0053","article-title":"Age-specific occurrence of HPV16- and HPV18-related cervical cancer","volume":"3","author":"De Sanjose","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.androl.2020.01.005_bib0425","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(14)60920-X","article-title":"Efficacy, safety, and immunogenicity of the human papillomavirus 16\/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study","volume":"384","author":"Skinner","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.androl.2020.01.005_bib0430","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of na HPV-16\/18 ASO4-adjuvanted prophylatic cervical cancer vaccine in women aged 15-55 years","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine."},{"key":"10.1016\/j.androl.2020.01.005_bib0435","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity and efficacy of quadrivalente human papillomavirus (types 6, 11,16,18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Mu\u00f1oz","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.androl.2020.01.005_bib0440","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age","volume":"105","author":"Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer."},{"key":"10.1016\/j.androl.2020.01.005_bib0445","first-page":"1","article-title":"Potential impact of nonavalent HPV vaccine in the prevention of high-grade cervical lesions and cervical cancer in Portugal","author":"Pista","year":"2017","journal-title":"Int J Gynecol Obstet."},{"key":"10.1016\/j.androl.2020.01.005_bib0450","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.androl.2020.01.005_bib0455","unstructured":"Centers for Disease Control and Prevention (CDC): Morbidity and mortality weekly report. FDA Licensure of Quadrivalent Human Papillomas Vaccine for use in males and guidance from the Advisory Committee on Immunization Practices 2010, 59(20): 630-632."},{"key":"10.1016\/j.androl.2020.01.005_bib0460","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJMp1110539","article-title":"The role of cost-effectiveness in U.S. vaccination policy","volume":"365","author":"Kim","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.androl.2020.01.005_bib0465","unstructured":"Vaccine Facts and Policy. Vaccination coverage rates in the United States. http:\/\/www.vaccinefactsandpolicy.org\/profiles. November 15, 2016."},{"key":"10.1016\/j.androl.2020.01.005_bib0470","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/journalofethics.2015.17.9.msoc1-1509","article-title":"vaccine: overcoming barriers to acceptation of a medical triumph","volume":"17","author":"Emberger","year":"2015","journal-title":"AMA J Ethics"},{"key":"10.1016\/j.androl.2020.01.005_bib0475","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jadohealth.2012.01.006","article-title":"Improving HPV vaccine delivery: a national study of parents and their adolescent sons","volume":"51","author":"Reiter","year":"2012","journal-title":"J Adolesc. Health"},{"key":"10.1016\/j.androl.2020.01.005_bib0480","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","article-title":"Impact of vaccinating boys and men against HPV in the United States","volume":"28","author":"Elbasha","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.androl.2020.01.005_bib0485","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00019053-200927020-00004","article-title":"Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review","volume":"27","author":"Marra","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.androl.2020.01.005_bib0490","doi-asserted-by":"crossref","unstructured":"Comiss\u00e3o de Vacinas da Sociedade de Infecciologia Pedi\u00e1trica e da Sociedade Portuguesa de Pediatria. Recomenda\u00e7\u00f5es sobre a Vacina\u00e7\u00e3o contra o Papiloma Virus Humano no G\u00e9nero Masculino. Acta Pediatr Port 2018, 49: 208-13.","DOI":"10.21069\/APP.2018.14090"}],"container-title":["Revista Internacional de Androlog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1698031X20300285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1698031X20300285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T21:51:18Z","timestamp":1594936278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1698031X20300285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":49,"alternative-id":["S1698031X20300285"],"URL":"https:\/\/doi.org\/10.1016\/j.androl.2020.01.005","relation":{},"ISSN":["1698-031X"],"issn-type":[{"value":"1698-031X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]}}}